Data gathered: April 26
AI Stock Analysis - Moderna (MRNA)
Analysis generated March 13, 2025. Powered by Chat GPT.
Moderna, Inc. is a biotechnology company that has garnered significant attention for its development of the mRNA technology platform. This platform is used to create vaccines and therapeutics, with their COVID-19 vaccine, mRNA-1273, being a notable success. The entity primarily focuses on pioneering mRNA science to address potentially severe diseases beyond COVID-19, including oncology, cardiology, infectious diseases, and rare genetic diseases.
Stock Alerts - Moderna (MRNA)
 |
Moderna | April 23 Price is up by 7.3% in the last 24h. |
|
Moderna | April 10 Price is down by -6.7% in the last 24h. |
|
Moderna | April 9 Price is up by 5.9% in the last 24h. |
|
Moderna | April 8 Price is down by -5.5% in the last 24h. |
Alternative Data for Moderna
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 140 | Sign up | Sign up | Sign up |
| Sentiment | 55 | Sign up | Sign up | Sign up |
| Webpage traffic | 206,000 | Sign up | Sign up | Sign up |
| Employee Rating | 68 | Sign up | Sign up | Sign up |
| Google Trends | 85 | Sign up | Sign up | Sign up |
| Patents | 228 | Sign up | Sign up | Sign up |
| 4chan Mentions | 1 | Sign up | Sign up | Sign up |
| Facebook Engagement | 40 | Sign up | Sign up | Sign up |
| Facebook Followers | 26,082 | Sign up | Sign up | Sign up |
| Reddit Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 170 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 109,531 | Sign up | Sign up | Sign up |
| Twitter Followers | 144,839 | Sign up | Sign up | Sign up |
| Twitter Mentions | 317 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 11,900 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 80 | Sign up | Sign up | Sign up |
| Lobbying Cost | $17,000 | Sign up | Sign up | Sign up |
| Business Outlook | 39 | Sign up | Sign up | Sign up |
| Linkedin Employees | 6,970 | Sign up | Sign up | Sign up |
About Moderna
Moderna is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. It focuses on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA. Moderna's technology platform inserts synthetic nucleoside-modified mRNA into human cells.
| Price | $27.22 |
| Target Price | Sign up |
| Volume | 7,710,000 |
| Market Cap | $10.5B |
| Year Range | $24.5 - $89.96 |
| Dividend Yield | 0% |
| PE Ratio | 24.73 |
| Analyst Rating | 16% buy |
| Earnings Date | May 1 '25 |
| Industry | Drug Manufacturers |
In the news
 |
Moderna (NasdaqGS:MRNA) Sees 11% Share Price Surge Over Last WeekApril 25 - Yahoo |
|
Can Moderna Keep the Beat Streak Alive This Earnings Season?April 25 - Yahoo |
 |
Sterling Capital Management LLC Sells 487 Shares of Moderna, Inc. (NASDAQ:MRNA)April 25 - ETF Daily News |
|
Cerity Partners LLC Trims Position in Moderna, Inc. (NASDAQ:MRNA)April 24 - ETF Daily News |
|
Moderna (MRNA) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseApril 24 - Yahoo |
|
Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Townsquare Capital LLCApril 23 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '24 | 966M | 739M | 227M | -1.12B | -1.12B | -2.910 |
| Q3 '24 | 1.86B | 514M | 1.34B | 13M | 79M | 0.030 |
| Q2 '24 | 241M | 156M | 85M | -1.28B | -1.23B | -3.330 |
| Q1 '24 | 167M | 132M | 35M | -1.18B | -1.12B | -3.070 |
| Q4 '23 | 2.81B | 929M | 1.88B | 217M | 208M | 0.550 |
Insider Transactions View All
| SAGAN PAUL filed to buy 312,027 shares at $31.8. March 4 '25 |
| Bancel Stephane filed to buy 9,210,686 shares at $31.5. March 4 '25 |
| Bancel Stephane filed to buy 9,153,193 shares at $31. March 4 '25 |
| Klinger Shannon Thyme filed to sell 20,446 shares at $44.7. December 10 '24 |
| Hoge Stephen filed to sell 1,443,904 shares at $43.3. December 4 '24 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$154.58 0% | 41 |
 |
Eli Lilly and CompanyLLY |
$884.54 0% | 68 |
 |
PfizerPFE |
$22.92 0% | 24 |
 |
AstrazenecaAZN |
$69.57 0% | 43 |
 |
AbbVieABBV |
$186.06 0% | 37 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Rob Bresnahan |
Mar 28, 25 | Buy | $1K - $15K |
| Julie Johnson |
Feb 13, 25 | Sell | $1K - $15K |
| Ro Khanna |
Oct 8, 24 | Buy | $1K - $15K |
Read more about Moderna (MRNA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Moderna?
The Market Cap of Moderna is $10.5B.
What is Moderna's PE Ratio?
As of today, Moderna's PE (Price to Earnings) ratio is 24.73.
When does Moderna report earnings?
Moderna will report its next earnings on May 1 '25.
What is the current stock price of Moderna?
Currently, the price of one share of Moderna stock is $27.22.
How can I analyze the MRNA stock price chart for investment decisions?
The MRNA stock price chart above provides a comprehensive visual representation of Moderna's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Moderna shares. Our platform offers an up-to-date MRNA stock price chart, along with technical data analysis and alternative data insights.
Does MRNA offer dividends to its shareholders?
As of our latest update, Moderna (MRNA) does not offer dividends to its shareholders. Investors interested in Moderna should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Moderna?
Some of the similar stocks of Moderna are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.